NASDAQ:BYSI
BeyondSpring Inc Stock News
$2.68
-0.300 (-10.07%)
At Close: May 28, 2024
Baird likes drug wholesalers in premarket analyst action
12:58pm, Friday, 07'th Feb 2020
Arcturus Therapeutics (NASDAQ:ARCT) initiated with Buy rating and $19 (70% upside) price target at Guggenheim.BeyondSpring (NASDAQ:BYSI) initiated with Buy rating and $25 (45% upside) price target at
Beyondspring (NASDAQ:BYSI) Rating Lowered to Hold at ValuEngine
08:30am, Thursday, 06'th Feb 2020
Beyondspring (NASDAQ:BYSI) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday, ValuEngine reports. Several other equities
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
01:00pm, Thursday, 23'rd Jan 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the ap
Beyondspring Inc (NASDAQ:BYSI) Expected to Announce Earnings of -$0.45 Per Share
11:52am, Monday, 20'th Jan 2020
Wall Street analysts predict that Beyondspring Inc (NASDAQ:BYSI) will report earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates
Beyondspring (NASDAQ:BYSI) Coverage Initiated by Analysts at Nomura
01:00pm, Monday, 13'th Jan 2020
Nomura began coverage on shares of Beyondspring (NASDAQ:BYSI) in a research report released on Friday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $34.00 price targe
William Blair Reaffirms Buy Rating for Beyondspring (NASDAQ:BYSI)
11:30am, Monday, 13'th Jan 2020
William Blair reiterated their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a report issued on Friday, AnalystRatings.com reports. BYSI has been the topic of several other reports. Nomura ini
Beyondspring (BYSI) Gets a Buy Rating from William Blair
06:40pm, Friday, 10'th Jan 2020
In a report issued on January 6,
Andy Hsieh
from William Blair reiterated a
Buy
rating on Beyondspring (
BYSI
–
Research Report
). The company’s shares closed last Monday at $17.64.
According to
T
Kadmon, BeyondSpring gain a bull as Nomura picks up coverage
03:05pm, Friday, 10'th Jan 2020
BeyondSpring (NASDAQ:BYSI) rises 2.7% and Kadmon Holdings (NYSE:KDMN) also gains 2.7% after Nomura Instinet initiates coverage of the two companies at Buy.BeyondSpring is testing plinabulin in mul
Morgan Stanley sees 15% upside in McKesson in premarket analyst action
12:32pm, Friday, 10'th Jan 2020
Aerie Pharmaceuticals (NASDAQ:AERI) initiated with Neutral rating and $27 (6% upside) price target at Bank of America.Aurinia Pharmaceuticals (AUP CN) initiated with Buy rating and C$35.26 (32% upside
BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
01:00pm, Monday, 06'th Jan 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced today the ap
BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies
01:00pm, Thursday, 19'th Dec 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer reviewed journal Cancer Chemothera
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update
12:00pm, Wednesday, 18'th Dec 2019
Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 Plinabulin’s Anti-Cancer and CIN Prevention Mechanism Published in Peer.
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
02:01pm, Wednesday, 11'th Dec 2019
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 St
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechani
